세계의 망막 의약품 시장(2024년) : 지도상 위축 및 기타 비삼출성 망막 질환

What's New:

This first-edition "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" estimates the prevalence of nonexudative retinal diseases and forecasts the treatment market by region for complement inhibitors, gene therapies, and more.

The report examines clinical-stage drug-development programs, reviews the development stages of drug- delivery platforms, and analyzes trends in doctor interest in complement inhibitors in both the United States and Western Europe, as well as patient dosing with complement inhibitors in the United States.

The "2024 Retinal Pharmaceuticals Market Report: GA and Other Nonexudative Diseases" analyzes the market for complement inhibitors, gene therapies, antioxidants, sustained-release devices, and other treatments for geographic atrophy, dry AMD, and additional nonexudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines disease prevalence, reviews patient economics and reimbursement, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 19 competitors are profiled, with discussion of their products, strategic market position, background, and outlook.

Contents:

This report explores a variety of topics intended to provide depth and context to the reader's understanding of market dynamics in this ophthalmic pharmaceutical segment. Our coverage includes:

• Discussions of nonexudative retinal diseases and their risk factors.
• Diagnosis and treatment of these diseases.
• A global view of retinal care and retina specialists.
• Pharmaceuticals and biologics in the marketplace for nonexudative retinal disease.
• Investigational agents in the development pipeline.
• Profiles of companies developing and marketing nonexudative retinal disease pharmaceuticals, plus a listing of additional companies with preclinical programs